Learn about May 2025’s top biotech deals, featuring major collaborations in RNA interference technology, small molecules, and antibodies.

NEW YORK, May 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has successfully closed the acquisition ... small and mid-cap biotechnology companies to ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Bankrupt genetic testing company 23andMe has been sold to Regeneron Pharmaceuticals for $256 million. The deal includes ...

Royalty Pharma plc (NASDAQ:RPRX), a leading funder of innovation across the biopharmaceutical industry with a market capitalization of $19.25 billion and an impressive 99% gross profit margin ...

Would the cost-cutting measures for U.S. prescription drugs proposed by the Trump administration on Monday hurt the biotech sector more than pharma? We asked Seeking Alpha analysts Stephen Ayers ...

Jefferies has predicted more small tuck-in deals to come, as biotechs struggle to access capital despite key clinical ...

By Michael Levenson 23andMe, the genetic testing company that was once valued at $6 billion but filed for bankruptcy in March, will be bought by Regeneron Pharmaceuticals, a biotechnology company ...

NEW YORK, May 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has successfully closed the acquisition of its external ... and non-profits through small and ...

Some key biotechnology acquisitions this year included Vertex Pharmaceuticals purchasing Alpine Immune Science and Novartis acquiring MorphySys for $5 and $2.9 billion USD, respectively.

Acquisition is Strong Strategic Fit for BioMarin, Adding INZ-701, a Phase 3 Enzyme Replacement Therapy Being Developed for Treatment of ENPP1 Deficiency ...